EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chromatin remodeler BRD9 represses transcription of PPARα target genes, including CPT1A to suppress lipid metabolism

Itsuki Yokoseki, Masataka Nakano, Kiamu Kurosawa, Yuichiro Higuchi, Shotaro Uehara, Nao Yoneda, Hiroshi Suemizu, Tatsuki Fukami, Miki Nakajima

Journal of Lipid Research · 2025-09 · 66 (9) · 100874

DOI: 10.1016/j.jlr.2025.100874 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2025-09. Verfasst von Itsuki Yokoseki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan. Hauptthemen laut MEDLINE: PPAR alpha, Carnitine O-Palmitoyltransferase, Transcription Factors, Lipid Metabolism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Government of Japan Ministry of Education Culture Sports Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator-activated receptor α (PPARα) regulates the transcription of fatty acid oxidation-related genes, such as carnitine palmitoyltransferase 1A (CPT1A), to maintain lipid homeostasis. Recent studies have suggested the involvement of switch/sucrose non-fermentable (SWI/SNF) complexes in nuclear receptor-mediated transcription. SWI/SNF complexes are chromatin remodeling factors classified into three complexes: canonical brahma-related gene 1-/brahma-associated factor (cBAF), polybromo BAF (PBAF), and non-canonical BAF (ncBAF). Among these, the key regulator of PPARα-mediated transcription remains unclear. In this study, we sought to clarify the significance of each SWI/SNF complex in PPARα-mediated transcription. Glycerol sedimentation assay revealed that PPARα interacts with ncBAF. The expression of multiple PPARα target genes, including CPT1A, was increased in HepG2 cells or primary human hepatocytes by inhibition or knockdown of bromodomain-containing protein 9 (BRD9), a specific subunit of ncBAF. Co-immunoprecipitation and pull-down assays demonstrated that PPARα interacts with ncBAF via BRD9. Chromatin immunoprecipitation- and formaldehyde-assisted isolation of regulatory elements-qPCR analyses revealed that BI-9564, an inhibitor of BRD9, can enhance the binding of PPARα to the PPRE on CPT1A by relaxing the chromatin structure. Interestingly, lipid accumulation in free fatty acid-treated HepG2 cells was attenuated by BI-9564 treatment, and the administration of BI-9564 to mice decreased their plasma triglyceride levels. Collectively, this study demonstrated that BRD9 negatively regulates PPARα-mediated transactivation and that inhibition of BRD9 can attenuate lipid accumulation by enhancing hepatic lipid metabolism. Thus, BRD9 could be considered a novel pharmacological target for dyslipidemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR alphaCarnitine O-PalmitoyltransferaseTranscription FactorsLipid MetabolismTranscription, GeneticHumansAnimalsHep G2 CellsMiceHepatocytesMaleBromodomain Containing Proteins

Stichwörter der Autor:innen

PPARsbromodomain-containing protein 9carnitine palmitoyltransferase 1Achromatin remodelingdyslipidemiaslipid dropletslipolysis and fatty acid metabolismswitch/sucrose non-fermentable complextranscription

Substanzen

PPAR alphaCarnitine O-PalmitoyltransferaseTranscription FactorsCPT1A protein, humanBRD9 protein, humanBromodomain Containing Proteins

Autor:innen und Institutionen

  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University, Kanazawa, Japan. Electronic address: mnakano@p…
  • Liver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Medicine and Life Science (CIEM), Kawasaki, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University, Kanazawa, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University, Kanazawa, Japan. Electronic address: nmiki@p.k…

Förderung

  • Japan Science and Technology Agency
  • Government of Japan Ministry of Education Culture Sports Science and Technology

Zitieren

APA

Yokoseki, I., Nakano, M., Kurosawa, K., Higuchi, Y., Uehara, S., Yoneda, N., Suemizu, H., Fukami, T., & Nakajima, M. (2025). Chromatin remodeler BRD9 represses transcription of PPARα target genes, including CPT1A to suppress lipid metabolism. Journal of Lipid Research, 66(9), 100874. https://doi.org/10.1016/j.jlr.2025.100874

Vancouver

Yokoseki I, Nakano M, Kurosawa K, Higuchi Y, Uehara S, Yoneda N, et al. Chromatin remodeler BRD9 represses transcription of PPARα target genes, including CPT1A to suppress lipid metabolism. Journal of Lipid Research. 2025;66(9):100874. doi:10.1016/j.jlr.2025.100874

BibTeX
@article{Yokoseki2025,
  author = {Yokoseki, Itsuki and Nakano, Masataka and Kurosawa, Kiamu and Higuchi, Yuichiro and Uehara, Shotaro and Yoneda, Nao and Suemizu, Hiroshi and Fukami, Tatsuki and Nakajima, Miki},
  title = {Chromatin remodeler BRD9 represses transcription of PPARα target genes, including CPT1A to suppress lipid metabolism},
  journal = {Journal of Lipid Research},
  year = {2025},
  volume = {66},
  number = {9},
  pages = {100874},
  doi = {10.1016/j.jlr.2025.100874}
}
Kostenlos starten →